SCHEDULE 13G/A: Millennium Updates Phathom Pharma Stake to 2.7%
Beneficial Ownership Update
Millennium Management and affiliated entities have updated their passive beneficial ownership in Phathom Pharmaceuticals, Inc., reporting a collective stake of 2.7% as of December 31, 2025.
Summary
- Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander collectively reported beneficial ownership of 2,082,180 shares of Phathom Pharmaceuticals, Inc. common stock, representing 2.7% of the class.
- Integrated Core Strategies (US) LLC, an affiliate, separately reported beneficial ownership of 1,255,161 shares, representing 1.6% of the class.
- The filing is an Amendment No. 3 to a Schedule 13G, indicating an update to a passive investment position.
- The reporting persons certified that the securities were not acquired for the purpose of changing or influencing control of Phathom Pharmaceuticals, Inc.
Sentiment
Score: 6
Explanation: The filing indicates continued passive investment by a prominent institutional investor group, Millennium Management, in Phathom Pharmaceuticals, which can be a positive signal of investor interest, though it provides no operational insights into the company.
Positives
- A significant institutional investor group, Millennium Management, maintains a notable passive stake in Phathom Pharmaceuticals, which can be viewed as a signal of continued investor interest.
Future Outlook
No forward-looking statements or guidance regarding Phathom Pharmaceuticals, Inc.'s operations or financial performance are provided in this ownership filing.
Industry Context
This filing primarily concerns an institutional investor's stake in Phathom Pharmaceuticals and does not provide broader industry trend analysis or competitive insights.
Stakeholder Impact
- Shareholders may view the continued significant stake by Millennium Management as a positive indicator of institutional confidence in Phathom Pharmaceuticals.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Date of event requiring the filing of this statement, reflecting the beneficial ownership position. |
| 01/26/2026 | Date the Schedule 13G/A amendment and Joint Filing Agreement were executed and filed. |
Keywords
Phathom Pharmaceuticals, Millennium Management, Institutional Ownership, Schedule 13G/A, Beneficial Ownership, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.